Adiponectin has been found to be decreased in NAFLD in previous studies too, which has a plausible explanation, since this adipokine is involved in energy metabolism through the reduction of plasmatic triglycerides, increased β-oxidation, and amelioration of glucose metabolism [5, 45]. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.